MYOV News and Press, Myovant Sciences Ltd. From 08/05/20

Sumitomo Dainippon Pharma ( OTCPK:DNPUF ) extends additional $200M low-interest, five-year term loan to Myovant Sciences (NYSE: MYOV ) , bringing its total financing support to $600M. More news on: Sumitomo Dainippon Pharma Co., Ltd., Myovant Sciences Ltd., Healthcare stocks n...

USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma to further support planned commercialization of relugolix across multiple indications Agreement with Sunovion Pharmaceuticals provides access to well-established commercial infrastructure curren...

Myovant Sciences ( MYOV ) is a clinical-stage biopharma that is developing its lead candidate, relugolix, in multiple late-state indications. Like Urovant Sciences ( UROV ) that I have previously written about, Myovant is majority-owned by Sumitomo ( DNPUF ) which provides significant support ...

Evercore ISI has added a healthy 19 stocks in a fresh resumption of its best SMID "core" ideas this month - the research team's very best small and mid-cap stocks. More news on: Cheniere Energy, Inc., WPX Energy, Inc., Chart Industries, Inc., Notable Calls, Healthcare stocks news, Energy s...

ObsEva SA ( OBSV -41.8% ) slumps on more than a 7x surge in volume on the heels of results from two Phase 3 clinical trials evaluating lead candidate linzagolix in women with heavy menstrual bleeding due to uterine fibroids. More news on: ObsEva SA, AbbVie Inc., Myovant Sciences Ltd., ...

Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic women Detailed data from ovulation inhibition study demonstrate 100% ovulation inhibition and 100% return of ovulation upon treatment discontinuati...

Forward Momentum brings together healthcare, research, and advocacy organizations Initial projects focus on increasing diversity in COVID-19 research and developing digital resources to support the overall health of men with prostate cancer CHICAGO, Ill.; SAN MATEO, Calif.; LOS ANG...

Karuna Therapeutics Reports Positive News for Acute Psychosis Treatment Karuna Therapeutics, Inc. ( KRTX ) reported that it plans to proceed with its clinical program assessing KarXT for the treatment of acute psychosis in patients with schizophrenia. The company stated that it has compl...

Myovant Sciences ( MYOV +11.4% ) announces results from a second Phase 3 clinical trial evaluating once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis-related pain that were consistent with t...

Fuwei Films (NASDAQ: FFHL ) +66%  on Q1 results . More news on: Fuwei Films (Holdings) Co., Ltd., Translate Bio, Inc., Recon Technology, Ltd., Stocks on the move, , Read more ...